Phase 2 N=10 Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure
Neonatal Abstinence Syndrome · Neonatal Opiate Withdrawal Syndrome
Primary: Buprenorphine Pharmacokinetics
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=63 Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome
Primary: Length of Treatment — 15; 28 days — p=<0.05
Phase 4 N=28 Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome
Primary: Length of Hospital Stay — 17.9; 16.1 days
Phase 2 N=196 Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women
Narcotic Addiction · Neonatal Abstinence Syndrome
Primary: Number of Participants With Neonatal Abstinence Syndrome — 22; 26 Participants — p=0.2
N/A N=29 Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
Substance Withdrawal Syndrome
Primary: Description of Signs and Symptoms of OIWS in Patients Who Scored Positive for Withdrawal Syndrome (OIWS) According to Diagnostic and Statistical Manual of Mental…
Phase 4 N=40 Treatment of Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome
Primary: Length of Treatment With Opioid Medication — 19.1; 17.7 days
Phase 4 N=31 Comparison Between Methadone and Morphine for Neonatal Opiate Withdrawal
Neonatal Abstinence Syndrome
Primary: Days of Treatment With Opioid Medication — 13.9; 22.9 days
Phase 4 N=31 NAS Treatment - Opiate Versus Non-Opiate
Neonatal Abstinence Syndrome
Primary: Finnegan Neonatal Abstinence Scoring System — 7.5; 8.5; 6.6; 5.7 scores on a scale
Phase 3 N=117 Improving Outcomes in Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome · Neonatal Opioid Withdrawal
Primary: Length of Hospital Stay (LOS) — 21.8; 23.2 days
Phase 3 N=120 Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain
Neonatal Abstinence Syndrome
Primary: Change in Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) — 0.5; 0.3; 1.0; 0.6 score on a scale
Phase 4 N=17 Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome · Neonatal Opioid Withdrawal · Neonatal Opioid Withdrawal Syndrome
Primary: Enrollment Rate — 17 Participants
Phase 2 N=42 Maternal Buprenorphine-naloxone Treatment and the Infant
Maternal Opioid Use Disorder · Opioid Exposed Infant
Primary: Fetal Heart Rate at 24 Weeks — 143.64 beats per minute
N/A N=8 tAN to Mitigate Withdrawal Behaviors in Neonates
Neonatal Abstinence Syndrome
Primary: Number of Subjects With no Adverse Events Related to Bradycardia (HR < 80 Bpm), Worsening of Swallowing or Feeding, Skin Irritation, or Elevation of Neonatal Infant Pain…
Phase 3 N=127 Fetal and Infant Effects of Maternal Buprenorphine Treatment
Neonatal Abstinence Syndrome
Primary: Fetal Heart Rate — 145.7; 143.3; 138.6; 136.3 beats per minute — p=0.001
N/A N=21 Acupuncture in Neonatal Abstinence Syndrome (NAS) Babies
Neonatal Abstinence Syndrome
Primary: Number of Participants With Skin Breakdown and / or Cellulitis — 0 participants
Phase 2 N=25 Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome
Primary: Time From Initiation of Adjunctive Therapy Until Hospital Discharge — 20; 33.8 Days
Phase 2 N=38 Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone
Opioid-related Disorders
Primary: Severity of Withdrawal Symptoms Measured Using the Clinical Opiate Withdrawal Scale (COWS) at Baseline and the Peak COWS up to 23.5 Hours After the First Administration…
Phase 3 N=175 RCT Comparing Methadone and Buprenorphine in Pregnant Women
Opioid Related Disorders · Pregnancy · Opioid Dependence
Primary: Child's Head Circumference Measurement (Measured at Birth) — 33.0; 33.8 cm
N/A N=208 Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome
Primary: Number of Participants Administered Morphine Treatment — 29; 31 Participants — p=.60
N/A N=19 Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment
Pregnancy · Drug Abuse
Primary: Fetal Heart Rate — 142.34 beats per minute
Phase 2 N=12 Oxytocin Treatment of Opioid Dependence
Opioid Dependence · Opioid Withdrawal
Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours
N/A N=185 Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach
Neonatal Opiate Withdrawal Syndrome
Primary: Time From Birth Until Medically Ready for Discharge — 14.9; 8.2 days — p=<0.0001
N/A N=21 Donor Human Milk in Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome
Primary: Percentage of Infants Achieving a GI Subscore >2 Over the Study Period — 39; 61 Percentage of participants — p=0.001
N/A N=36 Parent/Nurse Controlled Analgesia in the Neonatal Intensive Care Unit
Abdominal Surgery · Thoracic Surgery
Primary: Morphine Consumption — 0.014; 0.036 mg/kg/hr
Phase 3 N=38 The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels
Neonatal Abstinence Syndrome · Aromatherapy
Primary: Length of Hospitalization — 17.8; 11.4 days — p=0.03
N/A N=5 NSS-Bridge Device for Post-Cesarean Delivery Pain
Acute Pain · Cesarean Delivery
Primary: Opioid Consumption — 31 milligrams of oxycodone
N/A N=15 Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers
Substance-Related Disorders
Primary: Brain Regions With Increases or Decreases in Amplitude of Low Frequency Fluctuations (ALFF) Associated With Ondansetron Administration — 0.519; 0.562; 0.478; 0.486…
N/A N=29 Bringing Education Through Technology, Empathic Listening, and Research
Pregnancy Related
Primary: Feasibility of the Intervention — 21.5; 21.2 score on a scale
N/A N=16 Weighted Blankets With Infants With NAS
Neonatal Abstinence Syndrome
Primary: Change in Finnegan Score — -1.5167; -0.2549 score on a scale
N/A N=102 Optimizing Pregnancy and Treatment Interventions for Moms 2.0
Pregnancy, High Risk · Opioid-Related Disorders · Pregnancy Related
Primary: Opioid Use Disorder (OUD) and Other Substance Use Disorder (SUD) Treatment Linkage/Retention — -1.5; -8.8 Percentage of days